RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results
Ultragenyx shares are trading around $16 after gaining about 9% this week, rebounding from the $12.73 low hit earlier this month. On September 17, the FDA granted full approval to Fayuvi, the first therapy for Sanfilippo syndrome Type A, a rare and fatal childhood brain disease. Near-term focus now shifts from FDA approval to execution: … Read more